Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
16.08 NOK | -0.12% | 0.00% | -24.86% |
May. 14 | Transcript : Nykode Therapeutics AS, Q1 2024 Earnings Call, May 14, 2024 | |
May. 14 | Nykode Therapeutics AS Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | 140M 13.02M | Sales 2025 * | 191M 17.82M | Capitalization | 5.26B 490M |
---|---|---|---|---|---|
Net income 2024 * | -612M -57.07M | Net income 2025 * | -740M -69.01M | EV / Sales 2024 * | 28.7 x |
Net cash position 2024 * | 1.25B 116M | Net cash position 2025 * | 1.01B 93.76M | EV / Sales 2025 * | 22.2 x |
P/E ratio 2024 * |
-8.61
x | P/E ratio 2025 * |
-7.71
x | Employees | 176 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 55% |
Latest transcript on Nykode Therapeutics
1 day | -0.12% | ||
Current month | +1.90% | ||
1 month | +14.53% | ||
3 months | +6.49% | ||
6 months | -10.52% | ||
Current year | -24.86% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 47 | 06-12-31 | |
Michael Engsig
CEO | Chief Executive Officer | - | 07-02-28 |
Harald Gurvin
DFI | Director of Finance/CFO | 49 | 21-05-02 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bernd Seizinger
BRD | Director/Board Member | 67 | - |
Director/Board Member | 64 | - | |
Director/Board Member | - | - |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 775 M€ | -.--% | - | |
0.00% | 10 M€ | -3.35% | - | |
0.00% | 145 M€ | -1.49% | - | |
0.00% | 25 M€ | -2.35% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-10 | 16.08 | -0.12% | 51 239 |
24-06-07 | 16.1 | +5.99% | 1,427,269 |
24-06-06 | 15.19 | -0.59% | 377,674 |
24-06-05 | 15.28 | -1.36% | 281,201 |
24-06-04 | 15.49 | -3.67% | 559,166 |
Real-time Oslo Bors, June 10, 2024 at 03:07 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.86% | 491M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+2.24% | 22.78B | |
-10.44% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- VACC Stock